Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
Combining IT tilsotolimod with ipilimumab did not significantly improve the ORR or OS compared with ipilimumab alone in patients with anti-PD-1 advanced refractory melanoma.
Authors
- Gino K. In (ORCID: https://orcid.org/0000-0002-7060-5123)
- Ivana Krajsová (ORCID: https://orcid.org/0000-0002-1599-6424)
- M.‐T. Leccia (ORCID: https://orcid.org/0000-0003-1222-0396)
- Marcus O. Butler (ORCID: https://orcid.org/0000-0002-9840-7057)
- Luis de la Cruz‐Merino (ORCID: https://orcid.org/0000-0002-5333-0535)
- Shahram Rahimian
- Michele Maio (ORCID: https://orcid.org/0000-0002-0323-6321)
- Sylvie Négrier
- Massimo Guidoboni (ORCID: https://orcid.org/0000-0001-7703-790X)
- Sebastian Haferkamp (ORCID: https://orcid.org/0000-0002-3894-8345)
- Célèste Lebbé (ORCID: https://orcid.org/0000-0002-5854-7290)
- Paolo A. Ascierto (ORCID: https://orcid.org/0000-0002-8322-475X)
- Adi Diab (ORCID: https://orcid.org/0000-0002-0153-0244)
- Ellen Kapiteijn (ORCID: https://orcid.org/0000-0002-4814-6426)
- Petr Arenberger (ORCID: https://orcid.org/0000-0002-4800-5877)
- Michele Guida (ORCID: https://orcid.org/0000-0001-8411-0319)
- Jean‐Jacques Grob (ORCID: https://orcid.org/0000-0002-0667-153X)
- John Walker (ORCID: https://orcid.org/0000-0002-3006-6145)
- Stéphane Dalle (ORCID: https://orcid.org/0000-0002-3423-4548)
- Srinivas K. Chunduru
- Carmen Loquai
- Laurent Mortier (ORCID: https://orcid.org/0000-0002-2644-1790)
- Reham Abdel‐Wahab (ORCID: https://orcid.org/0000-0002-5432-5068)
- Caroline Robert (ORCID: https://orcid.org/0000-0002-9493-0238)
- Victoria Atkinson
Institutions
- Université Claude Bernard Lyon 1 (FR)
- University of Siena (IT)
- Centre National de la Recherche Scientifique (FR)
- University Health Network (CA)
- The University of Texas MD Anderson Cancer Center (US)
- University of Alberta (CA)
- Inserm (FR)
- The University of Queensland (AU)
- University of Toronto (CA)
- Université Paris Cité (FR)
- Aix-Marseille Université (FR)
- Université de Lille (FR)
- Université Paris-Saclay (FR)
- Leiden University Medical Center (NL)
- Centre Hospitalier Universitaire de Grenoble (FR)
- Institut Gustave Roussy (FR)
- Princess Margaret Cancer Centre (CA)
- Centre Hospitalier Universitaire de Lille (FR)
- University Hospital Regensburg (DE)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Centre Léon Bérard (FR)
- Hôpital Lyon Sud (FR)
- Vancouver Biotech (Canada) (CA)
- USC Norris Comprehensive Cancer Center (US)
- Gallipoli Medical Research Foundation (AU)
- Istituto Tumori Bari (IT)
- Instituto de Biomedicina de Sevilla (ES)
- Azienda Ospedaliera Universitaria Senese (IT)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Idera Pharmaceuticals (United States) (US)
- University Hospital Kralovske Vinohrady (CZ)
- General University Hospital in Prague (CZ)
- Universidad de Sevilla (ES)
- Université Grenoble Alpes (FR)
- Assiut University (EG)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1200/jco.24.00727
- Citations
- 5
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 3.99